OPICAPONE ADD-ON THERAPY IN LEVODOPA-CARBIDOPA INTESTINAL GEL INFUSION: which patient might benefit the most?
Objective: To explore the benefit of Opicapone (OPC) add-on to levodopa-carbidopa intestinal gel (LCIG) in different phenotypes of Parkinson’s Disease (PD) patients. Background: LCIG monotherapy…Defining nomenclature and age cut off for Early Onset Parkinson’s Disease: Recommendations from the Early Onset Parkinson’s Disease Task Force.
Objective: To define the nomenclature for Early Onset Parkinson Disease (EOPD) / Young Onset Parkinson Disease (YOPD), and the age at onset (AAO) cut off…A lower rate of hyposmia in non-Ashkenazi jewish patients with Parkinson’s disease: motor and non-motor disease characteristics in different ethnic groups in Israel
Objective: We aim to describe clinical aspects of Parkinson's disease (PD) in different ethnic groups in Israel, focusing on Non-Ashkenzi Jews (NAJ) ethnic groups vs.…Parkinson’s disease caregiver burden in rural India
Objective: To assess the caregiver burden and factors determining it in patients with PD. To assess the anxiety and depression amongst caregivers. Background: Patients with…PD+: A comprehensive, user-friendly mobile application for clinicians treating Parkinson’s Disease
Objective: We developed a mobile application that converts dopaminergic medication dosages and calculates total Levodopa (L-dopa) equivalent daily dose (LEDD) in a Parkinson’s Disease (PD)…The mitochondrial risk score and lifestyle factors are associated with age at onset in LRRK2 p.Gly2019Ser Parkinson’s disease.
Objective: To investigate the relationship between a mitochondrial risk score (MRS), lifestyle and age at onset (AAO) in LRRK2 G2019S Parkinson’s disease (PD). Background: PD…Inflammatory microglial and astroglial phenotype associated with pathological alpha-synuclein inclusions in the substantia nigra
Objective: To characterize neuroinflammatory gene expression in microglia and astrocytes associated with early alpha-synuclein (a-syn) inclusion formation. Background: Parkinson’s disease (PD) is characterized by alpha-synuclein…Protective mechanism of melatonin via heat shock protein in the MPP+-induced in vitro Parkinson’s disease model
Objective: The objective of this study was to investigate the protective properties of melatonin in an in vitro Parkinson’s disease (PD) model, especially focusing on…Month 24 results of a virtual longitudinal, observational study of Parkinson’s disease: The AT-HOME PD cohort
Objective: To describe the change in characteristics of Parkinson’s disease (PD) clinical trial participants over 24 months following trial participation in a remote, longitudinal observational…Examining the sex differences in the prevalence and incidence of Parkinson disease
Objective: The objective of this meta-analysis was to examine the male-to-female (M/F) incidence and prevalence of Parkinson disease. Background: Parkinson disease (PD) is a major…
- « Previous Page
- 1
- …
- 232
- 233
- 234
- 235
- 236
- …
- 338
- Next Page »